Bhat, Prasanna http://orcid.org/0000-0003-4759-3977
Aksenova, Vasilisa http://orcid.org/0000-0001-7325-3453
Gazzara, Matthew http://orcid.org/0000-0001-7710-4551
Rex, Emily A.
Aslam, Sadaf http://orcid.org/0000-0002-3748-4227
Haddad, Christina
Gao, Shengyan
Esparza, Matthew
Cagatay, Tolga
Batten, Kimberly
El Zahed, Sara S. http://orcid.org/0000-0002-0039-1780
Arnaoutov, Alexei http://orcid.org/0000-0001-7647-7217
Zhong, Hualin
Shay, Jerry W. http://orcid.org/0000-0001-5052-0627
Tolbert, Blanton S. http://orcid.org/0000-0003-2456-0443
Dasso, Mary http://orcid.org/0000-0002-5410-1371
Lynch, Kristen W.
GarcĂa-Sastre, Adolfo http://orcid.org/0000-0002-6551-1827
Fontoura, Beatriz M. A. http://orcid.org/0000-0001-8468-5315
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI154635, AI125524, 75N93021C00014, U19AI135972)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 6 September 2022
Accepted: 5 April 2023
First Online: 21 April 2023
Competing interests
: The authors declare no competing interests. The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, Paratus, CureLab Oncology, CureLab Veterinary, Synairgen and Pfizer, outside of the reported work. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott and Astrazeneca. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work.